<DOC>
	<DOCNO>NCT00028990</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop tumor cell divide stop grow die . Monoclonal antibody , bevacizumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill deliver cancer-killing substance . It yet know whether paclitaxel work well without bevacizumab treat breast cancer . PURPOSE : This randomized phase III trial see paclitaxel work well without bevacizumab treat patient locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Paclitaxel With Without Bevacizumab Treating Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time treatment failure patient locally recurrent metastatic breast cancer treat paclitaxel without bevacizumab . - Compare objective response rate , duration response , overall survival , time progression patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord disease-free interval ( 24 month vs 24 month ) , number metastatic site ( less 3 v 3 ) , treatment prior adjuvant chemotherapy ( yes v ) , estrogen receptor status ( positive v negative v unknown ) . Patients randomize one two treatment arm . - Arm I : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 follow bevacizumab IV 30-90 minute day 1 15 . - Arm II : Patients receive paclitaxel arm I . In arm , course repeat every 4 week absence disease progression unacceptable toxicity . Quality life assess baseline day 1 week 17 33 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 316-650 patient ( 158-325 per treatment arm ) accrue study within 31 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Locally recurrent disease amenable surgical resection curative intent OR Metastatic disease No HER2overexpressing ( 3+ ) breast cancer unless previously treat trastuzumab ( Herceptin ) Unknown HER2 status allow provide herceptinbased therapy inappropriate indicate No prior radiologic evidence CNS metastasis , include previously treat , resect , asymptomatic brain lesion leptomeningeal involvement head CT scan MRI Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No prior bleed diathesis Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal ( ULN ) ( 5 time ULN know liver involvement ) PT/PTT great 1.5 time normal INR great 1.5 time normal Renal : Creatinine great 2.0 mg/dL No proteinuria dipstick urinalysis Trace proteinuria allow Proteinuria le 500 mg 24hour urine collection proteinuria least 1+ urinalysis Cardiovascular : No clinically significant cardiovascular disease No myocardial infarction within past 12 month No unstable angina No prior deep vein thrombosis No grade 2 great peripheral vascular disease No uncontrolled congestive heart failure No uncontrolled hypertension ( systolic blood pressure great 170 mmHg diastolic blood pressure great 95 mm Hg ) No prior cerebrovascular accident Pulmonary : No prior pulmonary embolism Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No history seizures No nonhealing wound fracture No hypersensitivity paclitaxel , Cremophor EL , Chinese hamster ovary cell product , recombinant human antibodies No active infection require parenteral antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : No prior chemotherapy locally recurrent metastatic breast cancer At least 12 month since prior adjuvant neoadjuvant taxane therapy At least 3 week since prior adjuvant chemotherapy Endocrine therapy : At least 3 week since prior hormonal therapy locally recurrent metastatic breast cancer Radiotherapy : At least 3 week since prior radiotherapy No prior radiotherapy site disease No concurrent local radiotherapy pain control lifethreatening situation ( e.g , superior vena cava syndrome , spinal cord compression , CNS metastases ) Surgery : At least 4 week since prior major surgical procedure except placement vascular access device breast biopsy At least 7 day since prior minor surgical procedure , include placement access device fine needle aspiration Other : At least 10 day since prior anticoagulant therapy ( lowdose anticoagulant therapy maintain patency vascular access device allow ) At least 10 day since prior concurrent daily aspirin ( 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function No concurrent dipyridamole , ticlopidine , clopidogrel , cilostazol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>